- Home
- LIXT vs BREA Comparison
LIXT vs BREA Comparison
Compare LIXT & BREA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- BREA
- Stock Information
- Founded
- LIXT 2005
- BREA 2022
- Country
- LIXT United States
- BREA Ireland
- Employees
- LIXT N/A
- BREA N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- BREA Services-Misc. Amusement & Recreation
- Sector
- LIXT Health Care
- BREA Consumer Discretionary
- Exchange
- LIXT Nasdaq
- BREA Nasdaq
- Market Cap
- LIXT 12.4M
- BREA 14.8M
- IPO Year
- LIXT N/A
- BREA 2023
- Fundamental
- Price
- LIXT $4.47
- BREA $6.00
- Analyst Decision
- LIXT
- BREA
- Analyst Count
- LIXT 0
- BREA 0
- Target Price
- LIXT N/A
- BREA N/A
- AVG Volume (30 Days)
- LIXT 121.5K
- BREA 5.4K
- Earning Date
- LIXT 08-07-2025
- BREA 01-01-0001
- Dividend Yield
- LIXT N/A
- BREA N/A
- EPS Growth
- LIXT N/A
- BREA N/A
- EPS
- LIXT N/A
- BREA N/A
- Revenue
- LIXT N/A
- BREA $2,988,009.00
- Revenue This Year
- LIXT N/A
- BREA N/A
- Revenue Next Year
- LIXT N/A
- BREA N/A
- P/E Ratio
- LIXT N/A
- BREA N/A
- Revenue Growth
- LIXT N/A
- BREA 151.51
- 52 Week Low
- LIXT $0.64
- BREA $5.00
- 52 Week High
- LIXT $5.14
- BREA $19.50
- Technical
- Relative Strength Index (RSI)
- LIXT 58.29
- BREA 42.63
- Support Level
- LIXT $3.20
- BREA $5.71
- Resistance Level
- LIXT $4.60
- BREA $6.56
- Average True Range (ATR)
- LIXT 0.51
- BREA 0.24
- MACD
- LIXT 0.06
- BREA -0.05
- Stochastic Oscillator
- LIXT 78.53
- BREA 27.37
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.